Mucormycosis and chromoblastomycosis occurring in a patient with leprosy type 2 reaction under prolonged corticosteroid and thalidomide therapy;Mucormicose e cromoblastomicose em um paciente com reação hansênica tipo II sob terapia prolongada com corticosteróide e talidomida

Anais Brasileiros de Dermatologia

Volumn 87, Issue 5, 2012, Pages 767-771

  Basílio, Flávia Machado Alves ^a   Hammerschmidt, Mariana ^a   Mukai, Maira Mitsue ^a   Werner, Betina ^a   Pinheiro, Rosângela Lameira ^a   Moritz, Sandra ^b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b NONE

Author keywords

Chromoblastomycosis; Immunocompromised host; Leprosy; Mucormycosis

Indexed keywords

AMPHOTERICIN B; CLOFAZIMINE; DAPSONE; OFLOXACIN; PREDNISONE; RIFAMPICIN; THALIDOMIDE;

ADULT; ARTICLE; CASE REPORT; CHROMOMYCOSIS; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXCISION; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; MUCORMYCOSIS; MULTIBACILLARY LEPROSY; SKIN BIOPSY;

ADULT; CHROMOBLASTOMYCOSIS; GLUCOCORTICOIDS; HUMANS; IMMUNOCOMPROMISED HOST; LEPROSTATIC AGENTS; LEPROSY, MULTIBACILLARY; MALE; MUCORMYCOSIS; PREDNISONE; THALIDOMIDE;

EID: 84867757617     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962012000500017     Document Type: Article

References (10)

1. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30:851-6.
2. Kim DM, Hwang SM, Suh MK, Ha GY, Choi GS, Shin J, et al. Chromoblastomycosis Caused by Fonsecaea pedrosoi. Ann Dermatol. 2011;23:369-74.
3. Yeung CK, Cheng VC, Lie AK, Yuen KY. Invasive disease due to Mucorales: a case report and review of the literature. Hong Kong Med J. 2001;7:180-8.
4. Oh D, Notrica D. Primary Cutaneous mucormycosis in infants and neonates: case report and review of the literature. J Pediatr Surg. 2002;37:1607-11.
5. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48:1743-51
6. Mok CC, Que TL, Tsui EYK, Lam W. Mucormycosis in systemic lupus erythematosus. Semin Arthritis Rheum. 2003;33:115-24.
7. Sun HY, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis. 2011;11:301-11.
8. Lewis RE, Pongas GN, Albert N, Ben-Ami R, Walsh TJ, Kontoyiannis DP. Activity of Deferasirox in Mucorales: Influences of Species and Exogenous Iron. Antimicrob Agents Chemother. 2011;55:411-3.
9. Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol. 2009;47:3-15.
10. Palmeira VF, Kneipp LF, Rozental S, Alviano CS, Santos ALS. Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to ar rest key fungal biological processes and virulence. PLoS ONE. 2008;3:e3382.